Key result
Salivary proteomes share approximately 27% of proteins with plasma and offer a 48% less costly, non-invasive alternative for identifying acute myocardial infarction biomarkers, though none have yet been prospectively verified.
Why the study?
Saliva collection is non-invasive, convenient, and inexpensive compared to conventional venipuncture, offering promising potential for salivary proteins and peptides to serve as biomarkers for predicting acute myocardial infarction, particularly among high-risk type-2 diabetes mellitus patients.
Can salivary protein biomarkers be used to predict the onset of acute myocardial infarction among high-risk patients such as those with type-2 diabetes mellitus?
Can salivary protein biomarkers be used to predict the onset of acute myocardial infarction among high-risk patients such as those with type-2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
This narrative review highlights the potential of non-invasive, cost-effective salivary proteomics for diagnosing acute myocardial infarction in high-risk type 2 diabetes patients, while noting that prospective validation for predicting event onset is still lacking.
Human saliva plays a pivotal role in digesting food and maintaining oral hygiene. The presence of electrolytes, mucus, glycoproteins, enzymes, antibacterial compounds, and gingival crevicular fluid in saliva ensures the optimum condition of oral cavity and general health condition. Saliva collection has been proven non-invasive, convenient, and inexpensive compared to conventional venipuncture procedure. These distinctive advantages provide a promising potential of saliva as a diagnostic fluid. Through comprehensive analysis, an array of salivary proteins and peptides may be beneficial as biomarkers in oral and systemic diseases. In this review, we discuss the utility of human salivary proteomes and tabulate the recent salivary biomarkers found in subjects with acute myocardial infarction as well as respective methods employed. In a clinical setting, since acute myocardial infarction contributes to large cases of mortality worldwide, an early intervention using these biomarkers will provide an effective solution to reduce global heart attack incidence particularly among its high-risk group of type-2 diabetes mellitus patients. The utility of salivary biomarkers will make the prediction of this cardiac event possible due to its reliability hence improve the quality of life of the patients. Current challenges in saliva collection are also addressed to improve the quality of saliva samples and produce robust biomarkers for future use in clinical applications.
No takes yet. Share an insight, caveat, or question.
Rahim et al. (2015) conducted a review in Acute myocardial infarction and Type 2 diabetes mellitus. Salivary proteome biomarkers vs. Plasma/blood biomarkers was evaluated on Prediction and diagnosis of acute myocardial infarction onset. Salivary proteomes share approximately 27% of proteins with plasma and offer a 48% less costly, non-invasive alternative for identifying acute myocardial infarction biomarkers, though none have yet been prospectively verified.
Synapse has enriched 10 related papers. Consider them for comparative context: